Schubert & Co’s Pfizer PFE Stock Holding History

Schubert & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20	Closed	-$816	–	1097
2023 Q1	$816	Sell	20 -808	-98%	-$34.9K	﹤0.01%	1280
2022 Q4	$42.4K	Sell	828 -98	-11%	-$4.7K	0.04%	68
2022 Q3	$41K	Sell	926 -24	-3%	-$1.17K	0.04%	73
2022 Q2	$50K	Buy	950 +58	+7%	+$2.96K	0.05%	70
2022 Q1	$46K	Sell	892 -7,579	-89%	-$393K	0.05%	56
2021 Q4	$500K	Buy	+8,471	New	+$420K	0.51%	11

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Schubert & Co's PFE Position: Q2 2023 in Review

Schubert & Co sold out of Pfizer (PFE) in Q2 2023, closing a stake of 20 shares — an estimated $816 sold.

Schubert & Co first reported a position in PFE in Q4 2021 and held it in 6 quarters. The position peaked at $500K in Q4 2021. 3,042 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

Schubert & Co reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 20 Pfizer shares in Q2 2023, an estimated $816.
Schubert & Co first reported a position in Pfizer in Q4 2021 and held it in 6 quarters.
Schubert & Co's Pfizer position peaked at $500K in Q4 2021.
3,042 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.